THE BURDEN OF GASTROESOPHAGEAL REFLUX DISEASE AMONG PARTIAL/NON-RESPONDERS TO PROTON PUMP INHIBITOR THERAPY: A DATABASE STUDY IN US AND EUROPEAN COHORTS

(1) AstraZeneca R and D, Mölndal, Sweden

(2) Division of Gastroenterology, Eastern VA Medical School, Norfolk, VA

(3) Consumer Health Sciences, Princeton, NJ, United States

(4) Department of Gastroenterology, CHU Bordeaux, Saint André Hospital, Bordeaux, France



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS III session at Gastro 2009 UEGW/WCOG London (17th UEGW)